Using murine and human models and primary GBM tumor explants, we reveal the therapeutic potential of FcRn-silenced IL-12Fc to improve survival—both alone and in combination with radio or chemotherapy—with prolonged tissue retention and in the absence of relevant toxicity. The gene discussed is FCGRT; the disease is glioblastoma.